


Multifaceted α -Enaminone: Adaptable Building Block for Synthesis of Heterocyclic Scaffolds Through Conceptually Distinct 1,2-, 1,3-, 1,4-, and C–O Bond Forming Annulations

David Lankri,[†] Ghassan Albarghouti,[†] Mohamed Mahameed, and Dmitry Tsvetikhovskiy*^{ID}

The Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 91120, Israel

S Supporting Information

ABSTRACT: The new reactivity of α,β -unsaturated enaminones driven by their “dual electronic attitude” is reported. We introduce unexplored, α -enaminone synthones and reveal the unusual functionalities of these building blocks. The feasibility of this new concept is demonstrated in the direct functionalization of enaminone precursors, such as alkylation; 1,2-, 1,3-, or 1,4-addition; and C–O bond formation. The general and potential applicability is presented through the collective synthesis of several important classes of heterocycles via controlled cyclizations of easily accessible common precursors. The rapid composition of novel key α -enaminone synthones yields an assembly of oxazines, azaspirones, quinolinones, and quinolinols in a regio- and chemoselective fashion.



INTRODUCTION

Enaminoketones have attracted increased interest, particularly cyclic β -enaminones, which are known as important intermediates and have proven to be versatile building blocks for the synthesis of various heterocycles and natural products.¹ The N- and β -positions are their most reactive sites.² Acting as bisnucleophiles, β -enaminones are suitable platforms for construction of heterocyclic compounds, such as pyridine, pyrimidine, indolizidine, quinolizidine, and pyrrole derivatives, which are common motifs in alkaloid structures.³

Little is known about α -enaminones, apparently because they are often not directly accessible from the corresponding diketones.⁴ Compared with β -enaminones, the chemical behavior of the α -keto derivatives differs (Figure 1). They can




Figure 1. Dual electronic attitude of α -enaminone.

react as enamines (nucleophiles), as well as α,β -unsaturated ketones (electrophiles). Although many strategies are available for utilizing β -enaminones as building blocks, methods for the preparation of heterocycles using α -ketoenamines are limited.^{5–8}

In this study, we report novel reactivity of α,β -enaminones driven by their “dual electronic attitude”. We introduce unexplored, stable α -enaminone synthones, radically different from other

known α - or β -counterparts by their chemical behavior, and unlock unusual functionalities of these building blocks. We demonstrate general synthesis of several important classes of heterocycles via controlled cyclizations of an easily accessible α -enaminone common key precursors.

Oxazine, azaspirone, quinolines, quinolinone, and quinolinol structures are frequently observed as scaffold segments in various biochemical compounds. These architectures have been identified as building blocks of a numerous alkaloids, as well as other families of diverse, and often remotely related metabolites.⁹ Unfortunately, access to a large number of these target molecules, and their structural analogues, is either unknown or hindered by the multistep syntheses.¹⁰ An in-depth analysis of the introduced cores suggests that α -enaminone scaffold of Type-1 (Scheme 1) has the potential to serve as an operational, collective key unit for their construction via controlled intramolecular cyclizations.^{4,11} This would be the first attempt to link simple and single enaminone core with such a diverse, heterocyclic architectures. With this in mind, we developed a novel streamlined synthetic methodology that allows the rapid and collective composition of multiple targets using a single common precursor.

As we contemplate the possible approaches for delivering the desired targets, we first consider a 1,4-addition, generating quinolinone scaffolds (Scheme 1). Inevitably, to obtain bicyclic quinolinols, the 1,2-cyclization pathway must be constructed. In addition, if 1,2- and 1,4-additions are possible, the 1,3-cycloaddition becomes a plausible outcome, which would afford heterocyclic systems, such as azaspirones. We also illustrate


Received: March 3, 2017

Published: June 19, 2017


Scheme 1. Collective Synthesis of Heterocycles via Controlled Cyclization of α -Enaminone Precursor

Unprecedented 1,2-, 1,3-, 1,4- or C-O bond forming annulations

Regio-, Stereo-, and Chemoselective



Natural products from diverse biological origins share oxazine, quinoline and azaspirone heterocyclic cores




a C–O bond formation pathway that allows for direct synthesis of benzo- and methylene-oxazines. Intriguingly, designing a method to differentiate between these cyclization pathways would elegantly allow for the regio- and chemoselective collective delivery of a broad spectrum of conceptually different heterocycles. To the best of our knowledge, synthesis of all the previously mentioned scaffolds (and their structural analogues) using our approach has never been attempted.

RESULTS AND DISCUSSION

1,4-Addition. To test our hypothesis, a simple building block of Type-2 was prepared (Scheme 2; $R^1 = \text{Et}$; see Experimental Section) and selected as the model precursor. α -Enaminone **4** was obtained by reacting **2** with 1,3-dibromopropane in the presence of K_3PO_4 (1st equivalent of base). Surprisingly, an unexpected direct cyclization was observed. During the preparation of **4**, the alkylation of **2** with dibromopropane led to the isolation of a stable bicyclic quinolinone system **3** rather than the anticipated α -enaminone. We assumed that subsequent fast cyclization of **4** yields compound **3** as an exclusive single product.

Scheme 2. 1,4-Addition: Rapid Access Quinolinones from α -Enaminone Precursor (the Mechanism)



Presumably, an equilibrium between **5** and **4** is established due to prevailing enamine-type electronic behavior, suppressing the

enone-driven resonance. Subsequent nucleophilic attack leads to favorable 6-membered ring **6**. In the presence of a second equivalent of base, the deprotonation of **6** occurs, generating product **3**. No hydrolysis of **6** was detected, and only **3** was observed, which suggests that a very fast deprotonation may have occurred. This deprotonation allows formation of the thermodynamically favorable product, preserving its α,β -unsaturated functionality.

An efficient system for the desired transformation involves a combination of **2** with 10 equiv of 1,3-dibromopropane, 0.5 equiv of TBAB, and 2 equiv of K_3PO_4 at 100 °C in toluene (entry 10, Table 1). Control experiments were performed and

Table 1. Conditions Evaluation for Synthesis of Quinolinones: 2→3 [R¹ = Et]

entry	base	solvent	additive	yield (%) 3:2 ^a
1	K_2CO_3	THF		29:44
2	K_2CO_3	DMF		no reaction
3	K_2CO_3	MeCN		no reaction
4	K_2CO_3	pyridine		0:93
5	K_2CO_3	toluene		29:65
6	CS_2CO_3	toluene		26:51
7	<i>t</i> -BuOK	toluene		5:76
8	K_3PO_4	toluene		9:87
9	K_3PO_4	toluene	MS, TBAB 20%	13:81
10	K_3PO_4	toluene	MS, TBAB 50%	80:10 ^b
11	K_3PO_4	toluene	MS, TBAB 100%	70:15
12	K_2CO_3	toluene	MS, TBAB 50%	13:41 ^c


^aGC yields 0.2 mmol scale. ^bAll attempts to increase the conversion rate by elevating the temperature or prolonging the reaction time resulted in decomposition of starting materials. ^cThe decline in mass balance was due to the degradation of starting precursor during the reaction course.

demonstrated that no cyclization occurred in the absence of base. It is important to mention, that all attempts to decrease the amount of 1,3-dibromopropane resulted in incomplete conversion, and slow decomposition of starting material. To confirm the hypothesis and expand the scope of the substrates and targets employed, we conducted additional experiments with various α -enaminone precursors bearing different R¹ groups (compounds **2a–2d**; Table 2) under the optimized cyclization conditions. We detected exclusive 1,4-selectivity, which led to the generation of quinolinone scaffolds **3a–d**.¹²

In principle, the reaction of precursor **2** with dibromopropane could produce other possible reactive intermediate, **4a** (instead of **4**; Scheme 3A), that could give rise to quinolinone **3**. In order to differentiate among the pathways, the reaction of **2a** was carried out under the standard conditions but in the presence of 1-iodo-3-chloropropane (Scheme 3B). Compound **7** was then isolated as the only observable stable intermediate, and the structure was assigned on the basis of its NMR spectra and the results of GCMS analysis. No evidence for the presence of C-alkylated (1,4-type addition) product **8** was detected. It should be also noted that no cyclization outcome **3a**, or any other side-product, were formed in the reaction mixture.


C–O Bond Formation. An unexpected cyclization caught our attention when precursor **9** (R² ≠ H; Scheme 4) was subjected to 1,2-dibromoethane. During the preparation of α -enaminone **11**, the rapid cyclization led to the unforeseen isolation of stable oxazine, **10** (general structure). Surprisingly, **11** delivers two different outcomes (i.e., **10a**-methylene-oxazine or **10b**-benzoxazine) depending on the nature of the R²

Table 2. 1,4-Addition (Access to Quinolinones)^a



^aIsolated yields 0.5 mmol scale. Starting materials (in a range of 5–10%) were isolated. Prolonging the reaction time resulted in decomposition of **2**.

Scheme 3. Selective N-Alkylation Pathway



substituent (see Scheme 4). The best system for C–O bond formation involves a combination of **9** with 2 equiv of 1,2-dibromoethane, 0.2 equiv of TBAB, and 2 equiv of base at 100 °C. Table 3 lists the conditions evaluated for α -enaminone integrated with the aliphatic R² group (with DIEA as optimal base; entry 6). Then, the same set of variables was applied to the starting material, bearing an aromatic R² residue. For this setting, K_2CO_3 has been determined to be the best base. We believe that in the presence of base, the deprotonation of **11** is established (Scheme 4; two variants are possible depending on the R² substituent). The subsequent nucleophilic attack of the oxygen, which was driven by the enone transient attitude, leads further to more favorable 6-membered ring scaffolds that bear a conjugated double bond system (i.e., **10a**) or fully aromatized oxazine (i.e., **10b**).

Scheme 4. Annulation of α -Enaminone via C–O Bond Formation: Synthesis of Methylene- and Benzoxazines




Table 3. Conditions Evaluation for Synthesis of Oxazines: 9 \rightarrow 10 [R¹ = Ph, R² = Et]


entry	base	solvent	yield (%) 10a:9 ^a
1	K ₂ CO ₃	acetone	62:25
2	Na ₂ CO ₃	acetone	67:5
3	Cs ₂ CO ₃	acetone	17:51
4	K ₃ PO ₄	acetone	55:9
5	DIEA	acetone	74:3
6	DIEA	THF	85:0
7	DIEA	toluene	76:9
8	DIEA	DMF	13:0 ^b
9	DIEA	1,4-dioxane	64:18
10	DIEA	pyridine	no reaction
11	DIEA	MeCN	43:8 ^b

^aGC yields 0.2 mmol scale. ^bThe decline in mass balance was due to the degradation of starting precursor during the reaction course.

Representative examples of methylene- and benzoxazines, that were synthesized through C–O bond formation, shown in the Table 4. For this transformation, compounds with a variety of R¹- and R²-substituted Types-14 and 16 cores were prepared (precursors 14a–d, 16a–b; see Experimental Section) and subjected to the optimized conditions. It is also imperative to mention the exclusive *E*-selectivity was observed for cyclization products 15a–d and 17a–d. The critical stereochemical assignment of the bicyclic targets has been confirmed by NMR analysis (see SI spectral data).¹³

As shown in Table 4, the isolated yields of compounds 17a–b were significantly lower than of those of 15a–d. We attribute the apparent difference between these two groups to the nature of their R² residue. As proposed in the Scheme 5, an aromatic R² (in the presence of base) enables formation of a stable resonance form (19) of starting precursor 18, which dramatically slows down the alkylation step toward α -enaminone 20. This result is confirmed by our ability to recover a vast amount of unreacted starting materials. In contrast, the compounds integrated with aliphatic R² groups did not transform into the resonance form, and most likely undergo the desired alkylations to generate bicyclic products.


Table 4. Scope: C–O Bond Formation (Synthesis of Methylene- and Benzoxazines)^a




^aIsolated yields 0.5 mmol scale.

Scheme 5. Resonance Contribution to Alkylation Rate of Enaminone Precursor

Aromatic group enables formation of stable resonance form, which dramatically slows down the rate of alkylation step towards enaminone



1,3-Addition. With suitable access to quinolinones and oxazines in hand, we next experimented with other cyclizations. The reaction scope was extended to the synthesis of more challenging heterocycles using the same precursor (9) as a starting material (Table 5A). An interesting result was observed when 9 (R² \neq H) was subjected to 1,3-dibromopropane rather than 1,2-dibromoethane (as in the previously discussed transformation). In contrast to α -enaminones 4 (Scheme 2) and

Table 5. 1,3-Addition: Synthesis of Azaspirones, Plausible Mechanism, and the Substrate Scope^a

^aIsolated yields 0.5 mmol scale. ^bCs₂CO₃ was used as base (20 h).

11 (Scheme 4), the type-21 enaminones were stable (for various R¹ and R²). Following the exposure of enaminone 21 to basic conditions (the optimized reaction protocol is provided in Table 6, entry 12), we detected another unexpected and novel cyclization.

The derivatives of 21 were synthesized (see Experimental Section) and further subjected to the optimized cyclization conditions to generate products 24a–c, 26a–e, and 27a–e (Table 5C and D, respectively). Interestingly, of the two intermediates (22a and 22b; Table 5B), deprotonation primarily occurs at 22a regardless of the nature of R² group (aliphatic CH₂R or aromatic).

The endo-terminated cyclizations (24) were consistently observed as the dominant products for this transformation. We postulated that the formation of 23 (minor outcome) is suppressed due to the steric intramolecular hindrance from the R-group, and the alkyl bromide chain (22b; Table 5B). To test this hypothesis, enaminone 28 (integrated with the Me group as R²) was prepared and subjected to the optimized cyclization

Table 6. Conditions Evaluation for 1,3-Addition: 21 → 24 [R¹ = Et, R² = Ph]


entry	base	solvent	yield (%) ^a
1	Cs ₂ CO ₃	1,4-dioxane	no reaction
2	Cs ₂ CO ₃	THF	17
3	Cs ₂ CO ₃	DMF	29
4	Cs ₂ CO ₃	toluene	no reaction
5	Cs ₂ CO ₃	MeCN	55
6	Na ₂ CO ₃	MeCN	no reaction
7	K ₂ CO ₃	MeCN	10
8	K ₃ PO ₄	MeCN	6
9	NaOH	MeCN	11
10	DIEA	MeCN	no reaction
11	NaOMe	MeCN	77
12	NaOMe (2 equiv)	MeCN	96

^aGC yields 0.2 mmol scale.

conditions (Table 5E). The ratio of endo- and exoproducts (29 and 30, respectively) inverts with exo 30 being a major product, which further strengthens our core assumption.

Additionally, we investigated the effect of the temperature on selectivity of this reaction (1,3- addition). Therefore, we subjected enaminone **25b** (with R¹ and R² being Et groups; Scheme 6) to cyclization conditions at a lower temperature of 50 °C, utilizing NaOt-Bu as a base.¹⁴ We detected a similar ratio for products **26b** and **27b** (67:18).


Scheme 6. Effect of Temperature on the Selectivity



Notwithstanding the lack of selectivity, the successful construction of azaspirones via 1,3-cyclization of enaminone is remarkable. All pairs of *exo*- and *endo*- products were successfully separated, providing access to two conceptually different heterocycles. It should be also mentioned, that the exclusive *E*-selectivity observed for all exoterminated products **26a–e**. The critical stereochemical assignment was confirmed by NMR analysis.¹³

1,2-Addition. To complete the picture, we executed additional cyclizations to investigate the final 1,2-addition of the α -enaminone system. We followed the protocols designed for the radical cyclization of classical enones.¹⁵ Our attempts were carried out using the SmI₂/HMPA system.¹⁶ Here, type-31 α -enaminones (see Experimental Section for preparation) were subjected to radical cyclization conditions to provide bicyclic quinolinols **32** or quinoline **33**, however, both were obtained in low yields (Table 7). The two transformations were confirmed to undergo the desired termination, even though reduction and other side products were

Table 7. Radical 1,2-Cyclization: Direct Access to Quinolines and Quinolinols



detected in the reaction mixtures (quinoline was obtained if R² = aromatic). Despite our goal of enhancing the outcome of this transformation by varying the temperature, solvent, concentration, amount of SmI₂ or HMPA alternation, and order of reagent addition, our efforts were not successful. Nevertheless, radical reactions of **31a–c** afforded the desired products **32a**, **32b**, and **33a** (Table 7). To the best of our knowledge, these results represent the first examples of intramolecular cyclizations that incorporate quinolinols and quinolines from a simple enaminone. In these less effective cyclizations, the formation of **32a–b** and **33a** required 4 equiv of the Sm reagent, 10 equiv of HMPA, and 10 equiv of *tert*-butyl alcohol. Regardless of the mentioned drawbacks, the successful construction of the reported heterocycles via this type of transformation is unprecedented and unique.

CONCLUSION

We have reported the unprecedented reactivity of α,β -unsaturated enaminones driven by their “dual electronic attitude”. We introduced novel, stable α -enaminone synthones and discovered the unusual and novel functionalities of these building blocks. We have demonstrated that readily available α -enaminone precursors undergo facile cyclizations under basic conditions to afford a broad spectrum of heterocycles, such as azaspirones, quinolinones, quinolines, quinolinols, and oxazines. Accurate design of the starting material allows for specific and selective functionalization reactions across the unsaturated scaffold, enabling the preparation of diverse products. We believe that our methodology is ground-breaking in the field of basic chemical research, paves the way for novel retrosynthetic pathways, and may reasonably find potential application for the construction of highly complex systems.

EXPERIMENTAL SECTION

General Information. Unless otherwise noted, all reagents were purchased from commercial suppliers and used without further purification. Solvents used in the reactions were distilled from appropriate drying agents prior to use. Reactions were monitored by thin-layer chromatography (TLC) on silica gel 60 F₂₅₄ aluminum plates (Merck) and/or gas chromatography–mass spectrometry (GCMS). Visualization of compounds on TLC was accomplished by irradiation with UV light at 254 nm, iodine or vanillin stain. GCMS analysis was performed with “Agilent 7820A” gas chromatograph equipped with “Agilent 5975” quadrupole mass selective detector, using Agilent HP-5MS capillary column (30 m, 0.25 mm, 0.25 μ m film). Column chromatography was performed using silica gel 60 (particle size 0.04–0.063 mm) purchased from Sigma-Aldrich or aluminum oxide 90 active basic (particle size 0.063–0.200 mm) purchased from Merck. Proton and carbon NMR spectra were recorded on Varian Mercury 300 MHz or Varian Mercury 500 MHz spectrometer in deuterated solvent. Proton chemical shifts are reported in ppm (δ) relative to tetramethylsilane with the solvent resonance employed as the internal standard (CDCl₃, δ 7.26 ppm). ¹³C chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl₃, δ 77.0 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), integration and coupling constants (Hz). High-resolution mass spectra were determined on a Thermo Scientific LTQ Orbitrap XL (FTMS). Infrared spectra (IR) were recorded on a Thermo Fischer Scientific NICOLET-iS10 spectrometer.

General Procedure A. Synthesis of Quinolinones (1,4-Addition). To a flame-dried 15.0 mL reaction tube flushed with nitrogen, fitted with a magnetic stirring bar and rubber septum, were added imminone (1.0 equiv), K₃PO₄ (2.0 equiv), dibromopropane (10.0 equiv), TBAB (0.5 equiv), and molecular sieves (4 Å, 500 mg, 1.0 mmol) in dry toluene (0.1M) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo, and the

crude mixture was purified by flash chromatography to yield the desired product.

1-Propyl-1,3,4,5,6,7-hexahydroquinolin-8(2H)-one (3a). General Procedure A was applied. α -Iminone **2a** (77 mg, 0.5 mmol) prepared according to General Procedure E, K_3PO_4 (212 mg, 1.0 mmol), dibromopropane (1.01 g, 5.0 mmol), TBAB (83 mg, 0.25 mmol), and molecular sieves (4 Å, 250 mg) were mixed in dry toluene (5.0 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 4/96% MeOH/DCM) to yield **3a** in 78% yield (75 mg) as yellow liquid. 1H NMR (300 MHz, $CDCl_3$): δ 2.93–2.87 (m, 2H), 2.72–2.63 (m, 2H), 2.46–2.35 (m, 2H), 2.27 (t, $J = 6.2$ Hz, 2H), 2.11 (t, $J = 6.6$ Hz, 2H), 1.89 (p, $J = 6.3$ Hz, 2H), 1.71–1.52 (m, 4H), 0.85 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 196.2, 141.1, 139.2, 54.6, 47.6, 39.3, 31.1, 29.7, 22.5, 22.0, 18.5, 11.5. IR (neat): 2930, 2868, 2824, 1671, 1603, 1184 cm^{-1} . HRMS m/z : ($[M+Na]^+$) calcd for $C_{12}H_{19}NONa$ 216.1359; found 216.1356.

1-(2-(tert-Butyldimethylsilyloxy)ethyl)-1,3,4,5,6,7-hexahydroquinolin-8(2H)-one (3b). General Procedure A was applied. α -Iminone **2b** (135 mg, 0.5 mmol) prepared according to General Procedure E, K_3PO_4 (212 mg, 1.0 mmol), dibromopropane (1.01 g, 5.0 mmol), TBAB (83 mg, 0.25 mmol), and molecular sieves (4 Å, 250 mg) were mixed in dry toluene (5.0 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 5/95% ether/hexane) to yield **3b** in 58% yield (90 mg) as yellow liquid. 1H NMR (300 MHz, $CDCl_3$): δ 3.82 (t, $J = 6.7$ Hz, 2H), 3.00–2.93 (m, 2H), 2.87 (t, $J = 6.7$ Hz, 2H), 2.44–2.36 (m, 2H), 2.26 (t, $J = 6.2$ Hz, 2H), 2.11 (t, $J = 6.6$ Hz, 2H), 1.89 (p, $J = 6.3$ Hz, 2H), 1.67 (p, $J = 6.3$ Hz, 2H), 0.87 (s, 9H), 0.05 (s, 6H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 196.2, 140.7, 138.8, 62.9, 54.8, 49.3, 39.2, 31.0, 29.6, 25.9, 22.5, 18.9, 18.3, –5.3. IR (neat): 2927, 2855, 1673, 1251, 1099, 832, 774 cm^{-1} . HRMS m/z : ($[M+Na]^+$) calcd for $C_{17}H_{31}NO_2SiNa$ 332.2016; found 332.2019.

1-Isobutyl-1,3,4,5,6,7-hexahydroquinolin-8(2H)-one (3c). General Procedure A was applied. α -Iminone **2c** (84 mg, 0.5 mmol) prepared according to General Procedure E, K_3PO_4 (212 mg, 1.0 mmol), dibromopropane (1.01 g, 5.0 mmol), TBAB (83 mg, 0.25 mmol), and molecular sieves (4 Å, 250 mg) were mixed in dry toluene (5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 20/80% ethylacetate/hexane) to yield **3c** in 57% yield (59 mg) as yellow liquid. 1H NMR (300 MHz, $CDCl_3$): δ 2.95–2.86 (m, 2H), 2.56 (d, $J = 7.3$ Hz, 2H), 2.40 (t, $J = 7.4$ Hz, 2H), 2.27 (t, $J = 6.2$ Hz, 2H), 2.12 (t, $J = 6.6$ Hz, 2H), 2.02–1.84 (m, 3H), 1.73–1.61 (m, 2H), 0.93 (d, $J = 6.7$ Hz, 6H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 196.1, 141.5, 138.7, 59.8, 47.6, 39.5, 31.2, 29.8, 27.7, 22.4, 20.6, 18.3. IR (neat): 2951, 2866, 2822, 1671, 1602, 1435, 1184, 1121, 978 cm^{-1} . HRMS m/z : ($[M+Na]^+$) calcd for $C_{13}H_{21}NONa$ 230.1515; found 230.1519.

1-Benzyl-1,3,4,5,6,7-hexahydroquinolin-8(2H)-one (3d). General Procedure A was applied. α -Iminone **2d** (101 mg, 0.5 mmol) prepared according to General Procedure E, K_3PO_4 (212 mg, 1.0 mmol), dibromopropane (1.01 g, 5.0 mmol), TBAB (83 mg, 0.25 mmol), and molecular sieves (4 Å, 250 mg) were mixed in dry toluene (5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 20/80% ether/hexane) to yield **3d** in 54% yield (66 mg) as pale yellow solid (mp 86–89 °C). 1H NMR (300 MHz, $CDCl_3$): δ 7.48–7.43 (m, 2H), 7.34–7.19 (m, 3H), 3.93 (s, 2H), 2.80–2.76 (m, 2H), 2.50–2.44 (m, 2H), 2.31 (t, $J = 6.2$ Hz, 2H), 2.12 (t, $J = 6.5$ Hz, 2H), 1.95 (p, $J = 6.3$ Hz, 2H), 1.67–1.57 (m, 2H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 196.1, 140.7, 140.5, 139.8, 129.1, 128.1, 126.9, 55.7, 46.5, 39.4, 31.2, 29.8, 22.5, 17.8. IR (neat): 2943, 2928, 2864, 1661, 1611, 1161, 946, 746, 702 cm^{-1} . HRMS m/z : ($[M+H]^+$) calcd for $C_{16}H_{20}NO$ 242.1539; found 242.1538.

General Procedure B. Synthesis of Oxazines (C–O Formation). To a flame-dried 15 mL reaction tube, fitted with a magnetic stirring bar and a rubber septum connected to a nitrogen source, α -iminone (1.0 equiv), base (2.0 equiv), TBAB (0.2 equiv), dibromoethane (2.0 equiv) were mixed in dry THF (0.5M) at room temperature.

The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude mixture was purified by flash chromatography to yield the desired product.

5-Ethylidene-4-propyl-3,4,5,6,7,8-hexahydro-2H-benzo[b][1,4]-oxazine (15a). General Procedure B was applied. α -Iminone **14a** (91 mg, 0.5 mmol) prepared according to General Procedure E, Hunig's base (130 mg, 1.0 mmol), TBAB (33 mg, 0.1 mmol), and dibromoethane (188 mg, 1.0 mmol) were mixed in dry THF (1.0 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude mixture was purified by flash chromatography (basic alumina, 5/95% ether/hexane) to yield **15a** in 80% yield (84 mg) as yellow liquid. 1H NMR (300 MHz, $CDCl_3$): δ 5.48 (q, $J = 7.1$ Hz, 1H), 3.97–3.90 (m, 2H), 2.94 (t, $J = 4.3$ Hz, 2H), 2.56–2.47 (m, 2H), 2.22 (q, $J = 6.6$ Hz, 4H), 1.62–1.74 (m, 5H), 1.54 (h, $J = 7.4$ Hz, 2H), 0.88 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 140.0, 132.5, 122.0, 112.0, 59.5, 55.0, 45.7, 27.9, 25.3, 22.4, 21.8, 13.2, 11.5. IR (neat): 2958, 2929, 2869, 1624, 1455, 1353, 1143, 700 cm^{-1} . HRMS m/z : ($[M+H]^+$) calcd for $C_{13}H_{22}NO$ 208.1696; found 208.1690.

4-Benzyl-5-ethylidene-3,4,5,6,7,8-hexahydro-2H benzo[b][1,4]-oxazine (15b). General Procedure B was applied. α -Iminone **14b** (115 mg, 0.5 mmol) prepared according to General Procedure E, Hunig's base (130 mg, 1 mmol), TBAB (33 mg, 0.1 mmol), and dibromoethane (188 mg, 1.0 mmol) were mixed in dry THF (1.0 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (basic alumina, 5/95% ether/hexane) to yield **15b** in 75% yield (95 mg) as yellow liquid. 1H NMR (300 MHz, $CDCl_3$): δ 7.43 (d, $J = 7.6$ Hz, 2H), 7.35 (t, $J = 7.4$ Hz, 2H), 7.31–7.23 (m, 1H), 5.70 (q, $J = 7.2$ Hz, 1H), 3.99–3.95 (m, 2H), 3.93 (s, 2H), 2.90 (t, $J = 4.4$ Hz, 2H), 2.30 (q, $J = 6.7$ Hz, 4H), 1.77 (q, $J = 6.4$ Hz, 2H), 1.69 (d, $J = 6.9$ Hz, 3H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 141.0, 139.4, 132.2, 128.4, 127.8, 126.9, 121.3, 112.0, 59.4, 56.4, 45.7, 28.0, 25.4, 22.5, 13.3. IR (neat): 2957, 2928, 2864, 1642, 1624, 1194, 1146, 731, 696 cm^{-1} . HRMS m/z : ($[M+H]^+$) calcd for $C_{17}H_{22}NO$ 256.1696; found 256.1693.

5-Ethylidene-4-propyl-3,4,5,6,7,8-hexahydro-2H-benzo[b][1,4]-oxazine (15c). General Procedure B was applied. α -Iminone **14c** (149 mg, 0.5 mmol) prepared according to General Procedure E, Hunig's base (130 mg, 1.0 mmol), TBAB (33 mg, 0.1 mmol), and dibromoethane (188 mg, 1.0 mmol) were mixed in dry THF (1.0 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude mixture was purified by flash chromatography (basic alumina, 5/95% ether/hexane) to yield **15c** in 71% yield (95 mg) as yellow liquid. 1H NMR (300 MHz, $CDCl_3$): δ 5.54 (q, $J = 7.2$ Hz, 1H), 3.96 (t, $J = 4.4$ Hz, 2H), 3.76 (t, $J = 6.3$ Hz, 2H), 3.03 (t, $J = 4.4$ Hz, 2H), 2.73 (t, $J = 6.4$ Hz, 2H), 2.26–2.17 (m, 4H), 1.63–1.75 (m, 5H), 0.90 (s, 9H), 0.07 (s, 6H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 140.1, 132.4, 121.7, 112.4, 62.6, 59.7, 55.2, 47.1, 27.9, 25.9, 25.3, 22.4, 18.3, 13.2, –5.4. IR (neat): 2957, 2930, 2859, 1456, 1249, 1098, 837, 770 cm^{-1} . HRMS m/z : ($[M+H]^+$) calcd for $C_{18}H_{34}NO_2Si$ 324.2353; found 324.2354.

5-Ethylidene-4-(thiophen-2-ylmethyl)-3,4,5,6,7,8-hexahydro-2H-benzo[b][1,4]oxazine (15d). General Procedure B was applied. α -Iminone **14d** (118 mg, 0.5 mmol) prepared according to General Procedure E, Hunig's base (130 mg, 1.0 mmol), TBAB (33 mg, 0.1 mmol), and dibromoethane (188 mg, 1.0 mmol) were mixed in dry THF (1.0 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (basic alumina, 5/95% ether/hexane) to yield **15d** in 71% yield (93 mg) as yellow liquid. 1H NMR (300 MHz, $CDCl_3$): δ 7.27–7.22 (m, 1H), 6.99–6.91 (m, 2H), 5.77 (q, $J = 7.1$ Hz, 1H), 4.01 (s, 2H), 3.95 (t, $J = 4.4$ Hz, 2H), 3.00–2.92 (m, 2H), 2.36–2.23 (m, 4H), 1.82–1.67 (m, 5H). ^{13}C NMR (75 MHz, $CDCl_3$): δ 143.7, 141.1, 132.0, 126.5, 124.8, 124.6, 120.9, 112.3, 59.6, 51.8, 45.7, 27.9, 25.3, 22.4, 13.3. IR (neat): 2955, 2928, 2858, 1455, 1246, 1094, 830, 771 cm^{-1} . HRMS m/z : ($[M+H]^+$) calcd for $C_{15}H_{20}NOS$ 262.1260; found 262.1251.

5-Phenyl-4-propyl-3,4,5,6,7,8-hexahydro-2H-benzo[b][1,4]-oxazine (17a). General Procedure B was applied. α -Iminone **16a** (115 mg, 0.5 mmol) prepared according to General Procedure E, K_2CO_3

(138 mg, 1.0 mmol), TBAB (33 mg, 0.1 mmol), and dibromoethane (188 mg, 1.0 mmol) were mixed in dry THF (1.0 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (Silica gel, 2/98% ether/hexane) to yield **17a** in 26% yield (32 mg) as yellow liquid. ¹H NMR (300 MHz, CDCl₃): δ 7.57–7.52 (m, 2H), 7.41 (dd, *J* = 8.2, 6.6 Hz, 2H), 7.36–7.31 (m, 1H), 6.98–6.86 (m, 2H), 6.82 (dd, *J* = 7.1, 2.0 Hz, 1H), 4.13 (t, *J* = 4.4 Hz, 2H), 3.17 (t, *J* = 4.5 Hz, 2H), 2.54–2.46 (m, 2H), 1.26–1.07 (m, 2H), 0.47 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 147.7, 141.1, 136.0, 134.2, 129.1, 128.1, 126.7, 123.6, 121.9, 116.4, 60.3, 57.7, 45.6, 20.7, 11.1. IR (neat): 2964, 2860, 1580, 1461, 1433, 1240, 1006, 871, 775, 702 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₇H₁₉NONa 276.1357; found 276.1360.

5-(4-Chlorophenyl)-4-propyl-3,4,5,6,7,8-hexahydro-2H-benzo[*b*]-[1,4]oxazine (17b). General Procedure B was applied. α -Iminone **16b** (132 mg, 0.5 mmol) prepared according to General Procedure E, K₂CO₃ (138 mg, 1.0 mmol), TBAB (33 mg, 0.1 mmol), and dibromoethane (188 mg, 1.0 mmol) were mixed in dry THF (1.0 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 16 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (Silica gel, 2/98% Ether/hexane) to yield **17b** in 17% yield (49 mg) as yellow liquid. ¹H NMR (300 MHz, CDCl₃): δ 7.50–7.45 (m, 2H), 7.38–7.33 (m, 2H), 6.96–6.83 (m, 2H), 6.74 (dd, *J* = 7.2, 1.9 Hz, 1H), 4.10 (t, *J* = 4.5 Hz, 2H), 3.14 (t, *J* = 4.5 Hz, 2H), 2.50–2.42 (m, 2H), 1.23–1.10 (m, 2H), 0.49 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 139.4, 132.5, 130.4, 128.3, 123.4, 122.1, 116.7, 60.2, 57.7, 45.4, 20.7, 11.1. IR (neat): 2964, 2930, 2860, 1580, 1461, 1433, 1240, 1134, 1006, 871, 763, 702 cm⁻¹. HRMS *m/z*: ([M+H]⁺) calcd for C₁₇H₁₉ClNO 288.1150; found 288.1152.

General Procedure C. Synthesis of Azaspiro-decanones (1,3 Addition). To a flame-dried 15 mL reaction tube flushed with nitrogen, fitted with a magnetic stirring bar and rubber septum, were added α -enaminone (1.0 equiv., 0.5 mmol) and NaOMe (2.0 equiv., 1 mmol) in dry MeCN (1M) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography to yield the desired product.

10-(4-Chlorophenyl)-1-propyl-1-azaspiro[4.5]dec-9-en-6-one (24a). General Procedure C was applied. α -Enaminone **21a** (192 mg, 0.5 mmol) prepared according to General Procedure F and NaOMe (54 mg, 1.0 mmol) were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 5/95% ether/hexane) to yield **24a** in 73% yield (111 mg) as pale yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.47 (d, *J* = 6.6, 3.0 Hz, 2H), 7.22 (d, *J* = 4.9, 1.9 Hz, 2H), 6.13 (t, *J* = 4.2 Hz, 1H), 3.12–3.26 (m, 1H), 2.79 (q, *J* = 8.2 Hz, 1H), 2.64–2.36 (m, 6H), 1.88–1.77 (m, 3H), 1.69–1.50 (m, 2H), 1.45–4.32 (m, 1H), 0.84 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 213.1, 142.1, 139.3, 132.8, 130.7, 130.5, 127.5, 72.9, 51.1, 50.3, 39.5, 34.4, 24.3, 22.6, 22.5, 12.1. IR (neat): 2958, 2931, 2871, 2846, 1704, 1486, 1174, 1089, 1015, 822 cm⁻¹. HRMS *m/z*: ([M+H]⁺) calcd for C₁₈H₂₃ClNO 304.1463; found 304.1467.

10-Phenyl-1-propyl-1-azaspiro[4.5]dec-9-en-6-one (24b). General Procedure C was applied. α -Enaminone **21b** (175 mg, 0.5 mmol) prepared according to General Procedure F and NaOMe (54 mg, 1.0 mmol) were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 5/95% ether/hexane) to yield **24b** in 72% yield (97 mg) as pale yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.48 (d, *J* = 8.2 Hz, 2H), 7.23 (d, *J* = 8.1 Hz, 3H), 6.12 (t, *J* = 4.2 Hz, 1H), 3.18 (td, *J* = 8.1, 2.7 Hz, 1H), 2.78 (q, *J* = 7.4 Hz, 1H), 2.67–2.58 (m, 2H), 2.54–2.38 (m, 4H), 1.90–1.69 (m, 3H), 1.68–1.62 (m, 1H), 1.59–1.49 (m, 1H), 1.45–1.39 (m, 1H), 0.83 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 213.4, 143.1, 141.0, 130.3, 129.3, 127.4, 126.9, 73.1, 51.2, 50.3, 39.5, 34.4, 24.4, 22.6, 22.5, 12.1. IR (neat): 2957, 2930, 2846, 1704, 1442, 1174, 1075, 759, 698 cm⁻¹. HRMS *m/z*: ([M+H]⁺) calcd for C₁₈H₂₄NO 270.18524; found 270.18506.

10-Phenyl-1-(thiophen-2-ylmethyl)-1-azaspiro[4.5]dec-9-en-6-one (24c). General Procedure C was applied. α -Enaminone **21c** (202 mg, 0.5 mmol) prepared according to General Procedure F, Cs₂CO₃ (326 mg, 1.0 mmol) were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 20 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (Silica gel, 5/95% ether/hexane) to yield **24c** in 75% yield (122 mg) as yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.62–7.54 (m, 2H), 7.40–7.28 (m, 3H), 7.16 (d, *J* = 5.1, 1.3 Hz, 1H), 6.93–6.86 (m, 1H), 6.81 (d, *J* = 3.4 Hz, 1H), 6.20 (t, *J* = 4.3 Hz, 1H), 4.05–3.86 (m, 2H), 3.10–2.99 (m, 1H), 2.89 (q, *J* = 8.0 Hz, 1H), 2.80–2.68 (m, 1H), 2.60–2.46 (m, 3H), 2.14–2.01 (m, 1H), 2.01–1.78 (m, 2H), 1.77–1.56 (m, 1H). ¹³C NMR (75 MHz, CDCl₃): δ 212.9, 144.2, 143.1, 140.6, 130.8, 129.4, 127.6, 127.1, 126.1, 125.2, 124.5, 73.2, 50.7, 48.0, 39.1, 35.2, 24.5, 22.5. IR (neat): 2958, 2845, 1704, 1444, 1169, 758, cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₂₀H₂₁NOSNa 346.1236; found 346.1236.

26a (endo) and 27a (exo). General Procedure C was applied. α -Enaminone **25a** (178 mg, 0.5 mmol) prepared according to General Procedure F and NaOMe (54 mg, 1.0 mmol), were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 5/95% ether/hexane) to yield 54% of **26a** and 5% of **27a** (65 mg and 7 mg, respectively).

10-Ethyl-1-(thiophen-2-ylmethyl)-1-azaspiro[4.5]dec-9-en-6-one (26a). Pale yellow solid (mp 49–51 °C). ¹H NMR (300 MHz, CDCl₃): δ 7.17 (d, *J* = 5.0, 1.3 Hz, 1H), 6.92–6.84 (m, 2H), 5.88–5.79 (m, 1H), 3.96 (d, *J* = 14.1 Hz, 1H), 3.72 (d, *J* = 14.0 Hz, 1H), 3.17–3.07 (m, 1H), 2.92 (q, *J* = 7.8 Hz, 1H), 2.72–2.58 (m, 1H), 2.44–2.30 (m, 4H), 2.24–2.11 (m, 1H), 2.06–1.94 (m, 1H), 1.90–1.78 (m, 3H), 1.12 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 213.6, 145.6, 143.9, 126.2, 124.1 (2C) 123.7, 74.0, 50.7, 47.9, 38.7, 35.4, 24.9, 22.6, 22.1, 13.3. IR (neat): 2957, 2924, 2848, 1703, 1177, 722 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₆H₂₁NOSNa 298.1236; found 298.1237.

10-Ethylidene-1-(thiophen-2-ylmethyl)-1-azaspiro[4.5]dec-6-one (27a). Pale yellow solid (mp 53–55 °C). ¹H NMR (300 MHz, CDCl₃): δ 7.19 (dd, *J* = 4.8, 1.6 Hz, 1H), 6.93 (d, *J* = 5.2 Hz, 2H), 6.07 (q, *J* = 7.0 Hz, 1H), 4.14 (d, *J* = 14.5 Hz, 1H), 3.72 (d, *J* = 14.5 Hz, 1H), 3.22–3.10 (m, 1H), 2.95–2.84 (m, 1H), 2.79–2.68 (m, 1H), 2.54–2.47 (m, 2H), 2.27–2.10 (m, 2H), 1.97–1.71 (m, 3H), 1.70–1.56 (m, 5H). ¹³C NMR (75 MHz, CDCl₃): δ 213.8, 145.8, 139.2, 126.3, 124.1, 123.9, 118.5, 79.5, 50.9, 48.6, 39.9, 38.1, 25.9, 22.9, 21.7, 13.3. IR (neat): 2926, 2841, 1702, 1454, 1134, 851, 696 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₆H₂₁NOSNa 298.1236; found 298.1236.

26b (endo) and 27b (exo). General Procedure C was applied. α -Enaminone **25b** (151 mg, 0.5 mmol) prepared according to General Procedure F and NaOMe (54 mg, 1.0 mmol) were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (Silica gel, 5/95% ether/hexane) to yield 71% of **26b** and 16% of **27b** (78 mg and 18 mg, respectively) as pale yellow oils.

10-Ethyl-1-propyl-1-azaspiro[4.5]dec-9-en-6-one (26b). ¹H NMR (300 MHz, CDCl₃): δ 5.81–5.72 (m, 1H), 3.20–3.08 (m, 1H), 2.84–2.73 (m, 1H), 2.60–2.46 (m, 1H), 2.45–2.21 (m, 5H), 2.18–1.96 (m, 2H), 1.90–1.69 (m, 4H), 1.54–1.19 (m, 2H), 1.03 (t, *J* = 7.5 Hz, 3H), 0.81 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 214.5, 144.2, 123.1, 73.6, 50.7, 50.4, 39.3, 34.7, 24.3, 22.7, 22.6, 21.9, 13.2, 11.8. IR (neat): 2958, 2931, 2872, 2847, 1712, 1458, 1180, 1085 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₄H₂₃NONa 244.1672; found 244.1679.

10-Ethylidene-1-propyl-1-azaspiro[4.5]dec-6-one (27b). ¹H NMR (300 MHz, CDCl₃): δ 5.81–5.70 (m, 1H), 3.25–3.17 (m, 1H), 2.93–2.83 (m, 1H), 2.75–2.55 (m, 2H), 2.47–2.38 (m, 2H), 2.33–2.25 (m, 1H), 2.18–2.03 (m, 2H), 1.89–1.82 (m, 1H), 1.76–1.70 (m, 3H), 1.64 (d, *J* = 6.9 Hz, 3H), 1.57–1.39 (m, 3H), 0.86 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 214.4, 139.6, 117.8, 51.7, 51.0, 40.1, 38.1, 29.7, 25.8, 22.9, 22.7, 21.6, 13.2, 12.0. IR (neat): 2956, 2928, 2668, 1707, 1456, 1197, 1153, 1096 cm⁻¹. HRMS *m/z*: ([M+H]⁺) calcd for C₁₄H₂₄NO 222.1852; found 222.1855.

26c (endo) and 27c (exo). General Procedure C was applied. α -Enaminone **25c** (175 mg, 0.5 mmol) prepared according to General Procedure F and NaOMe (54 mg, 1.0 mmol) were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 5/95% ether/hexane) to yield 63% of **26c** and 15% of **27c** (85 mg and 20 mg, respectively).

1-Benzyl-10-ethyl-1-azaspiro[4.5]dec-9-en-6-one (26c). Pale yellow solid (mp 52–55 °C). ¹H NMR (300 MHz, CDCl₃): δ 7.34–7.16 (m, 5H), 5.90–5.82 (m, 1H), 3.76–3.51 (m, 2H), 3.04–2.93 (m, 1H), 2.85 (h, *J* = 6.5 Hz, 1H), 2.73–2.57 (m, 1H), 2.49–2.28 (m, 4H), 2.25–2.14 (m, 1H), 2.05–1.76 (m, 4H), 1.11 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 214.0, 143.9, 140.5, 128.1, 128.0, 126.5, 123.8, 73.9, 52.8, 50.5, 39.0, 35.0, 24.7, 22.8, 22.1, 13.3. IR (neat): 2961, 2847, 1709, 1494, 1452, 1153, 733, 697 cm⁻¹. HRMS *m/z*: ([M+H]⁺) calcd for C₁₈H₂₄NO 270.1852; found 270.1857.

1-Benzyl-10-ethylidene-1-azaspiro[4.5]decan-6-one (27c). Pale yellow solid (mp 57–58 °C). ¹H NMR (300 MHz, CDCl₃): δ 7.38 (d, *J* = 7.0 Hz, 2H), 7.32 (t, *J* = 7.5 Hz, 2H), 7.26–7.17 (m, 1H), 5.97 (q, *J* = 7.0 Hz, 1H), 3.88 (d, *J* = 14.4 Hz, 1H), 3.65 (d, *J* = 14.6 Hz, 1H), 3.11–3.02 (m, 1H), 2.90–2.79 (m, 1H), 2.77–2.67 (m, 1H), 2.57–2.48 (m, 2H), 2.30–2.13 (m, 2H), 1.97–1.68 (m, 4H), 1.67–1.59 (m, 4H). ¹³C NMR (75 MHz, CDCl₃): δ 214.1, 140.9, 139.6, 128.1, 128.0, 126.3, 118.3, 79.7, 53.1, 50.7, 40.0, 37.7, 25.9, 22.9, 21.7, 13.3. IR (neat): 2926, 2849, 1703, 1492, 1453, 1209, 1152, 1136, 735, 697 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₈H₂₃NONa 292.1672; found 292.1676.

26d (endo) and 27d (exo). General Procedure C was applied. α -Enaminone **25d** (190 mg, 0.5 mmol) prepared according to General Procedure F and NaOMe (54 mg, 1.0 mmol) were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 5/95% EtOAc/hexane) to yield 50% of **26d** and 15% of **27d** (75 mg and 22 mg, respectively).

10-Ethyl-1-(4-methoxybenzyl)-1-azaspiro[4.5]dec-9-en-6-one (26d). Pale yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.19 (d, *J* = 8.4 Hz, 2H), 6.83 (d, *J* = 8.6 Hz, 2H), 5.88–5.80 (m, 1H), 3.79 (s, 3H), 3.68–3.47 (m, 2H), 2.99–2.91 (m, 1H), 2.88–2.79 (m, 1H), 2.69–2.59 (m, 1H), 2.55–2.30 (m, 4H), 2.23–2.12 (m, 1H), 2.01–1.77 (m, 4H), 1.11 (t, *J* = 7.5 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 214.0, 158.3, 143.9, 132.6, 129.1, 123.7, 113.5, 73.7, 55.2, 52.1, 50.4, 39.1, 35.0, 24.6, 22.7, 22.1, 13.3. IR (neat): 2960, 2834, 1709, 1510, 1241, 1168, 1036, 810 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₉H₂₅NO₂Na 322.1778; found 322.1777.

(E)-10-Ethylidene-1-(4-methoxybenzyl)-1-azaspiro[4.5]decan-6-one (27d). Yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.29 (d, *J* = 8.5 Hz, 2H), 6.86 (d, *J* = 8.6 Hz, 2H), 5.97 (q, *J* = 6.9 Hz, 1H), 3.85–3.76 (m, 4H), 3.57 (d, *J* = 13.9 Hz, 1H), 3.07–2.96 (m, 1H), 2.88–2.68 (m, 2H), 2.57–2.47 (m, 2H), 2.30–2.14 (m, 2H), 1.97–1.70 (m, 5H), 1.66 (d, *J* = 5.7 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 214.1, 158.2, 143.8, 139.6, 133.0, 129.1, 118.3, 115.0, 113.5, 79.5, 67.5, 55.2, 52.5, 50.6, 40.0, 37.7, 25.9, 22.9, 21.6, 13.3. IR (neat): 2923, 2853, 1693, 1490, 1457, 1243, 1202, 1158, 1146, 742, 690 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₉H₂₅NO₂Na 322.1778; found 322.1777.

26e (endo) and 27e (exo). General Procedure C was applied. α -Enaminone **25e** (209 mg, 0.5 mmol) prepared according to General Procedure F and NaOMe (54 mg, 1.0 mmol) were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 5/95% ether/hexane) to yield 60% of **26e** and 3% of **27e** (101 mg and 5 mg, respectively) as pale yellow oils.

1-(2-((tert-Butyldimethylsilyloxy)ethyl)-10-ethyl-1-azaspiro[4.5]dec-9-en-6-one (26e). ¹H NMR (300 MHz, CDCl₃): δ 5.78–5.72 (m, 1H), 3.65–3.51 (m, 2H), 3.22–3.13 (m, 1H), 2.99–2.88 (m, 1H), 2.70–2.47 (m, 3H), 2.42–2.11 (m, 4H), 2.05–1.91 (m, 1H), 1.90–1.64 (m, 4H), 1.03 (t, *J* = 7.4 Hz, 3H), 0.87 (s, 9H), 0.02 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 214.0, 144.1, 123.2, 74.2, 62.7, 51.6, 51.5, 38.8, 34.8, 26.0, 24.7, 23.0, 21.9, 18.4, 12.9, –5.3. IR (neat): 2956, 2928, 2845,

1714, 1253, 1103, 832, 774 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₉H₃₅NO₂SiNa 360.2329; found 360.2329.

1-(2-((tert-Butyldimethylsilyloxy)ethyl)-10-ethylidene-1-azaspiro[4.5]decan-6-one (27e). ¹H NMR (300 MHz, CDCl₃): δ 5.81 (q, *J* = 6.4 Hz, 1H), 3.77–3.65 (m, 2H), 3.26–3.18 (m, 1H), 3.00–2.78 (m, 2H), 2.76–2.65 (m, 1H), 2.58–2.47 (m, 1H), 2.45–2.38 (m, 2H), 2.20–2.01 (m, 2H), 1.94–1.66 (m, 3H), 1.68–1.45 (m, 5H), 0.89 (s, 9H), 0.05 (s, 6H). ¹³C NMR (75 MHz, CDCl₃): δ 214.0, 139.5, 118.2, 80.1, 62.8, 52.4, 51.9, 40.0, 37.8, 26.0, 25.8, 22.9, 21.8, 18.4, 13.2, –5.31, –5.27. IR (neat): 2954, 2928, 2856, 1709, 1254, 1104, 834, 775 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₉H₃₅NO₂SiNa 360.2329; found 360.2327.

29 (endo) and 30 (exo). General Procedure C was applied. α -Enaminone **28** (144 mg, 0.5 mmol) prepared according to General Procedure F and NaOMe (54 mg, 1.0 mmol) were mixed in dry MeCN (0.5 mL) at room temperature. The reaction mixture was refluxed at 100 °C for 1 h. The mixture was then concentrated in vacuo and the crude product was purified by flash chromatography (silica gel, 5/95% ether/hexane) to yield 17% of **29** and 46% of **30** (18 mg and 48 mg, respectively) as pale yellow oils.

10-Methyl-1-propyl-1-azaspiro[4.5]dec-9-en-6-one (29). ¹H NMR (300 MHz, CDCl₃): δ 5.82–5.71 (m, 1H), 3.21–3.09 (m, 1H), 2.88–2.78 (m, 1H), 2.61–2.50 (m, 1H), 2.48–2.37 (m, 1H), 2.38–2.21 (m, 4H), 1.99–1.72 (m, 4H), 1.71 (s, 3H), 1.55–1.28 (m, 2H), 0.84 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 214.3, 138.9, 125.7, 73.3, 50.5, 50.4, 39.3, 34.4, 24.4, 22.7, 22.6, 17.7, 11.9. IR (neat): 2957, 2930, 2848, 1711, 1448, 1184, 1083, 807 cm⁻¹. HRMS *m/z*: ([M+H]⁺) calcd for C₁₃H₂₂NO 208.1696; found 208.1697.

10-Methylene-1-propyl-1-azaspiro[4.5]decan-6-one (30). ¹H NMR (300 MHz, CDCl₃): δ 5.19–5.13 (m, 1H), 4.89–4.84 (m, 1H), 3.32–3.22 (m, 1H), 3.00–2.89 (m, 1H), 2.72–2.62 (m, 1H), 2.55 (dt, *J* = 14.0, 4.3 Hz, 1H), 2.48–2.29 (m, 4H), 2.17–2.03 (m, 1H), 1.95–1.72 (m, 4H), 1.64–1.50 (m, 2H), 1.46–1.36 (m, 1H), 0.86 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 213.5, 150.1, 109.4, 79.7, 51.8, 51.2, 40.5, 38.7, 33.6, 23.6, 22.9, 21.7, 11.9. IR (neat): 2955, 2934, 2870, 2843, 1708, 1457, 1100, 1082, 905 cm⁻¹. HRMS *m/z*: ([M+H]⁺) calcd for C₁₃H₂₂NO 208.1696; found 208.1696.

General Procedure D. Synthesis of Quinolines and Quinolinols (1,2-Addition). In a flame-dried 100 mL reaction flask flushed with nitrogen, fitted with a magnetic stirring bar and rubber septum a solution of SmI₂ in THF (0.1 M, 4.0 equiv) was added dropwise (1 mL/min) to a solution of α -enaminone (1.0 equiv, 0.5 mmol), HMPA (10.0 equiv, 5.0 mmol), and *t*-BuOH (10.0 equiv, 5.0 mmol) in dry THF (0.05 M) at 0 °C. The reaction mixture was then stirred under inert atmosphere for 1 h at room temperature and quenched with aqueous saturated NH₄Cl. The mixture was extracted with EtOAc, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The crude mixture was purified by flash chromatography to yield the desired product.

1-Benzyl-8-ethyl-1,3,4,5,6,7-hexahydroquinolin-4a(2H)-ol (32a). General Procedure D was applied. A solution of SmI₂ in THF (20.0 mL, 0.1 M, 2.0 mmol) was added dropwise to a solution of α -enaminone **31a** prepared according to General Procedure G, (199 mg, 0.5 mmol), HMPA (895 mg, 5.0 mmol), and *t*-BuOH (370 mg, 5.0 mmol) in dry THF (10.0 mL) at 0 °C. The reaction mixture was stirred under inert atmosphere for 1 h at room temperature and quenched with aqueous saturated NH₄Cl. The mixture was then dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 10/90% EtOAc/hexane) to yield **32a** in 43% yield (58 mg) as mixture of 2 diastereomers as yellow liquid. ¹H NMR (300 MHz, CDCl₃): δ 7.42–7.29 (m, 4H), 7.28–7.21 (m, 1H), 4.39 (d, *J* = 14.5 Hz, 1H), 3.83 (d, *J* = 14.3 Hz, 1H), 2.79–2.90 (m, 1H), 2.60 (t, *J* = 12.8, 2.9 Hz, 1H), 2.28 (q, *J* = 7.5 Hz, 2H), 2.17–2.02 (m, 2H), 2.01–1.79 (m, 2H), 1.79–1.71 (m, 1H), 1.59–1.70 (m, 2H), 1.56–1.38 (m, 2H), 1.29–1.14 (m, 1H), 0.99 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃): δ 142.4, 141.0, 130.1, 128.3, 128.1, 126.7, 69.4, 60.3, 48.1, 39.4, 39.3, 29.3, 24.8, 18.4, 18.1, 12.8. IR (neat): 2930, 2872, 1710, 1459, 942, 734, 697 cm⁻¹. HRMS *m/z*: ([M+Na]⁺) calcd for C₁₈H₂₅NONa 294.1828; found 294.1824.

8-Ethyl-1-propyl-1,3,4,5,6,7-hexahydroquinolin-4a(2H)-ol (32b). General Procedure D was applied. A solution of SmI₂ in THF (20 mL,

0.1 M, 2.0 mmol) was added dropwise to a solution of α -enaminone **31b** prepared according to General Procedure G, (175 mg, 0.5 mmol), HMPA (895 mg, 5.0 mmol), and *t*-BuOH (370 mg, 5.0 mmol) in dry THF (10.0 mL) at 0 °C. The reaction mixture was stirred under inert atmosphere for 1 h at room temperature and quenched with aqueous saturated NH_4Cl . The mixture was then dried over anhydrous Na_2SO_4 , filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (basic alumina, 5/95% EtOAc/hexane) to yield **32b** in 37% yield (41 mg) as mixture of 2 diastereomers as yellow liquid. ^1H NMR (300 MHz, CDCl_3): Mixture of diastereomers: δ 3.09–2.92 (m, 2H), 2.70–2.58 (m, 2H), 2.16–2.06 (m, 3H), 2.04–1.95 (m, 2H), 1.86–1.71 (m, 2H), 1.61–1.53 (m, 2H), 1.52–1.38 (m, 4H), 1.34–1.24 (m, 2H), 0.95 (t, $J = 7.6$ Hz, 3H), 0.87 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): Major diastereomer: δ 142.7, 127.7, 69.3, 58.4, 49.2, 39.6, 38.9, 29.5, 25.1, 23.0, 19.6, 18.7, 13.0, 11.6. Minor diastereomer, characteristic signals: δ 79.9, 57.9, 53.6, 42.4, 34.7, 34.1, 23.6, 21.0, 19.4, 19.0, 12.1, 6.7. IR (neat): 3486, 2956, 2925, 2870, 1709, 1670, 1457, 1376, 1088 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{14}\text{H}_{26}\text{NO}$ 224.2009; found 224.2014.

8-(4-Chlorophenyl)-1-propyl-1,2,3,4-tetrahydroquinoline (33a). General Procedure D was applied. A solution of SmI_2 in THF (20.0 mL, 0.1 M, 2.0 mmol) was added dropwise to a solution of α -enaminone **31c** prepared according to General Procedure G, (216 mg, 0.5 mmol), HMPA (895 mg, 5.0 mmol), and *t*-BuOH (370 mg, 5.0 mmol) in dry THF (10.0 mL) at 0 °C. The reaction mixture was stirred under inert atmosphere for 1 h at room temperature and quenched with aqueous saturated NH_4Cl . The mixture was then dried over anhydrous Na_2SO_4 , filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 1/99% EtOAc/hexane) to yield **33a** in 30% yield (48 mg) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 7.42–7.32 (m, 2H), 7.25 (d, $J = 8.4$ Hz, 2H), 7.15–7.01 (m, 1H), 6.67–6.53 (m, 1H), 6.47 (d, $J = 7.5$, 1.2 Hz, 1H), 3.35–3.21 (m, 4H), 2.57 (t, $J = 6.3$ Hz, 2H), 1.84 (p, $J = 6.5$ Hz, 2H), 1.71–1.62 (m, 2H), 0.97 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 146.0, 145.5, 140.9, 132.4, 130.5, 128.0, 126.6, 119.5, 116.9, 109.9, 53.7, 49.4, 26.6, 22.2, 19.5, 11.6. IR (neat): 2951, 2925, 2870, 1714, 1582, 1484, 1459, 1199, 1085, 1017, 831, 774, 719 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{18}\text{H}_{21}\text{ClN}$ 286.1357; found 286.1365.

General Procedure E. Preparation of Precursors α -Iminones. Napier et al.^{4c} A solution of epoxide precursor¹¹ (1.0 equiv) and amine (1.5 equiv) in 3:1 mixture of methanol:water was refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude mixture was purified by flash chromatography to yield the desired product.

2-(Propylamino)cyclohex-2-en-1-one (2a).¹⁷ General Procedure E was applied. The corresponding epoxide precursor 7-oxabicyclo[4.1.0]heptan-2-one (1.0 g, 9.0 mmol) and propylamine (800 mg, 13.5 mmol) were mixed in 9.0 mL of methanol, and 3.0 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 10/90% EtOAc/hexane) to yield the desired product in 63% yield (865 mg) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 5.32 (t, $J = 4.7$ Hz, 1H), 4.04 (s, 1H), 2.71 (t, $J = 7.0$ Hz, 2H), 2.42–2.32 (m, 2H), 2.28 (q, $J = 5.6$ Hz, 2H), 1.85 (p, $J = 6.2$ Hz, 2H), 1.50 (h, $J = 7.3$ Hz, 2H), 0.87 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 195.7, 140.6, 110.6, 44.9, 37.9, 24.5, 23.5, 22.1, 11.7. IR (neat): 3399, 2958, 2931, 2872, 1671, 1626, 1488, 1167, 867 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_9\text{H}_{16}\text{NO}$ 154.1226; found 154.1228.

2-((tert-Butyldimethylsilyloxy)ethyl)amino)cyclohex-2-en-1-one (2b). General Procedure E was applied. The corresponding epoxide precursor 7-oxabicyclo[4.1.0]heptan-2-one (1.0 g, 9 mmol) and 2-((tert-butyl-dimethylsilyloxy)ethan-1-amine (1.9 g, 10.8 mmol) were mixed in 9.0 mL of methanol, and 3.0 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 20/80% EtOAc/hexane) to

yield the desired product in 44% yield (1.1 g) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 5.43 (t, $J = 4.7$ Hz, 1H), 4.44 (s, 1H), 3.73 (t, $J = 5.5$ Hz, 2H), 2.92 (t, $J = 5.5$ Hz, 2H), 2.49–2.38 (m, 2H), 2.33 (q, $J = 5.6$ Hz, 2H), 1.91 (p, $J = 6.1$ Hz, 2H), 0.86 (s, 9H), 0.02 (s, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ 195.6, 146.0, 140.6, 111.3, 61.3, 45.1, 37.9, 25.9, 24.5, 23.5, 18.3, –5.4. IR (neat): 2928, 2856, 1675, 1629, 1472, 1629, 1472, 1252, 1101, 830, 775 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{14}\text{H}_{28}\text{NO}_2\text{Si}$ 270.1884; found 270.1887.

2-(Isobutylamino)cyclohex-2-en-1-one (2c).¹⁸ General Procedure E was applied. The corresponding epoxide precursor 7-oxabicyclo[4.1.0]heptan-2-one (1.0 g, 9.0 mmol) and 2-methylpropan-1-amine (988 mg, 13.5 mmol) were mixed in 9.0 mL of methanol, and 3.0 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 8/92% ether/hexane) to yield the desired product in 74% yield (1.1 g) as light brown liquid. ^1H NMR (300 MHz, CDCl_3): δ 5.35 (t, $J = 4.7$ Hz, 1H), 4.15 (s, 1H), 2.64–2.55 (m, 2H), 2.46–2.37 (m, 2H), 2.32 (q, $J = 5.6$ Hz, 2H), 1.89 (p, $J = 6.1$ Hz, 2H), 1.81–1.72 (m, 1H), 0.89 (d, $J = 6.7$, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ 195.8, 140.7, 110.5, 51.1, 37.9, 27.6, 24.5, 23.5, 20.6 (2C). IR (neat): 3403, 2953, 2868, 2827, 1671, 1626, 1488, 1333, 1201, 1167, 1126, 866 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{10}\text{H}_{18}\text{NO}$ 168.1383; found 168.1388.

2-(Benzylamino)cyclohex-2-en-1-one (2d).¹⁹ General Procedure E was applied. The corresponding epoxide precursor 7-oxabicyclo[4.1.0]heptan-2-one (900 mg, 8.0 mmol) and benzylamine (1.71 g, 16.0 mmol) were mixed in 8.0 mL of methanol and 2.3 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 20/80% EtOAc/hexane) to yield the desired product in 32% yield (1.02 g) as pale green solid (mp 56–59 °C). ^1H NMR (300 MHz, CDCl_3): δ 7.20–7.36 (m, 5H), 5.42 (t, $J = 4.7$ Hz, 1H), 4.60 (s, 1H), 4.08 (d, $J = 4.3$ Hz, 2H), 2.59–2.41 (m, 2H), 2.33 (q, $J = 5.6$ Hz, 2H), 1.94 (p, $J = 6.3$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3): δ 195.8, 140.4, 139.0, 128.5, 127.4, 127.1, 111.8, 47.6, 37.9, 24.5, 23.5. IR (neat): 3407, 2928, 1659, 1619, 1488, 1361, 1208, 742, 700 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{13}\text{H}_{16}\text{NO}$ 202.1226; found 202.1224.

3-Ethyl-2-(propylamino)cyclohex-2-en-1-one (14a). General Procedure E was applied. The corresponding epoxide precursor 6-ethyl-7-oxabicyclo[4.1.0]heptan-2-one (1.42 g, 10.1 mmol) and propylamine (0.89 g, 15.2 mmol) were mixed in 10.0 mL of methanol and 3.3 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (Silica gel, 10/90% EtOAc/hexane) to yield the desired product in 48% yield (880 mg) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 3.69 (s, 1H), 2.64 (t, $J = 7.1$ Hz, 2H), 2.38–2.15 (m, 6H), 1.87–1.69 (m, 2H), 1.39 (q, $J = 7.3$ Hz, 2H), 1.01 (t, $J = 7.6$ Hz, 3H), 0.82 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 196.6, 143.4, 139.5, 51.3, 37.1, 28.9, 26.2, 23.6, 22.1, 11.6, 11.5. IR (neat): 3337, 2960, 2874, 1662, 1625, 1486, 1168 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{11}\text{H}_{20}\text{NO}$ 182.1539; found 182.1539.

2-(Benzylamino)-3-ethylcyclohex-2-en-1-one (14b). General Procedure E was applied. The corresponding epoxide precursor 6-ethyl-7-oxabicyclo[4.1.0]heptan-2-one (2.1 g, 15.0 mmol) and benzylamine (2.4 g, 22.5 mmol) were mixed in 15.0 mL of methanol and 5.0 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 10/90% EtOAc/hexane) to yield the desired product in 58% yield (1.99 g) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 7.35–7.20 (m, 5H), 3.95 (s, 2H), 2.29–2.45 (m, 6H), 1.96–1.76 (m, 2H), 1.11 (t, $J = 7.5$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 197.0, 141.0, 138.8, 128.9, 128.1, 128.0, 127.1, 48.3, 37.2, 32.0, 23.0, 22.3, 11.3. IR (neat): 2965,

2935, 2875, 1660, 1624, 1453, 1184, 1161, 734, 697 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{15}\text{H}_{19}\text{N}\text{ONa}$ 252.1364; found 252.1357.

2-((2-((tert-Butyldimethylsilyloxy)ethyl)amino)-3-ethylcyclohex-2-en-1-one (14c). General Procedure E was applied. The corresponding epoxide precursor 6-ethyl-7-oxabicyclo[4.1.0]heptan-2-one (1.3 g, 9.4 mmol) and 2-((tert-butylidimethylsilyloxy)ethan-1-amine (2.46 g, 14.1 mmol) were mixed in 9.0 mL of methanol and 3.0 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 1:1 DCM/hexane) to yield the desired product in 41% yield (1.17 g) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 3.68 (t, $J = 5.6$ Hz, 2H), 2.91 (t, $J = 5.6$ Hz, 2H), 2.48–2.24 (m, 6H), 1.91 (q, $J = 6.3$ Hz, 2H), 1.10 (t, $J = 7.5$ Hz, 3H), 0.91 (d, $J = 2.2$ Hz, 9H), 0.06 (d, $J = 2.1$ Hz, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ 196.4, 143.4, 139.4, 62.5, 51.0, 37.3, 29.1, 26.2, 25.9, 22.2, 18.3, 11.7, –5.4. IR (neat): 2952, 2928, 2856, 1666, 1627, 1462, 1253, 1103, 830, 774 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{16}\text{H}_{32}\text{NO}_2\text{Si}$ 298.2197; found 298.2196.

3-Ethyl-2-((thiophen-2-ylmethyl)amino)cyclohex-2-en-1-one (14d). General Procedure E was applied. The corresponding epoxide precursor 6-ethyl-7-oxabicyclo[4.1.0]heptan-2-one (1.4 g, 10.0 mmol) and thiophen-2-ylmethanamine (1.7 g 15.0 mmol) were mixed in 10.0 mL of methanol and 3.3 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 60/40% DCM/hexane) to yield the desired product in 48% yield (1.13 g) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 7.15 (dd, $J = 4.9, 1.5$ Hz, 1H), 6.97–6.80 (m, 2H), 4.18 (s, 1H), 4.12 (s, 2H), 2.39 (q, $J = 7.0$ Hz, 6H), 1.87 (p, $J = 6.3$ Hz, 2H), 1.11 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 196.5, 145.8, 143.4, 138.6, 126.6, 124.9, 124.3, 47.7, 37.2, 29.0, 26.3, 22.1, 11.6. IR (neat): 3319, 2930, 2872, 1656, 1619, 1464, 1160, 697 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{13}\text{H}_{17}\text{NOSNa}$ 258.0923; found 258.0923.

2-(Propylamino)-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (16a). General Procedure E was applied. The corresponding epoxide precursor 6-phenyl-7-oxabicyclo[4.1.0]heptan-2-one (1.2 g, 6.3 mmol) and propylamine (560 mg, 9.5 mmol) were mixed in 6.0 mL of methanol and 2.0 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 10/90% EtOAc/hexane) to yield the desired product in 48% yield (630 mg) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 7.44–7.39 (m, 2H), 7.33 (t, $J = 7.7$ Hz, 2H), 7.26–7.19 (m, 1H), 4.27 (s, 1H), 2.67 (t, $J = 6.0$ Hz, 2H), 2.58–2.46 (m, 2H), 2.32 (t, $J = 7.0$ Hz, 2H), 2.03 (q, $J = 6.4$ Hz, 2H), 1.27 (h, $J = 7.2$ Hz, 2H), 0.69 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 197.0, 141.0, 138.8, 128.9, 128.1, 128.0, 127.1, 48.3, 37.2, 32.0, 23.0, 22.3, 11.3. IR (neat): 3341, 2956, 2920, 2859, 1660, 1468, 1328, 1187, 1128, 765, 670 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{13}\text{H}_{20}\text{NO}$ 230.1538; found 230.1539.

4'-Chloro-2-(propylamino)-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (16b). General Procedure E was applied. The corresponding epoxide precursor 6-(4-chlorophenyl)-7-oxabicyclo[4.1.0]heptan-2-one (1.59 g, 7.15 mmol) and propylamine (610 mg, 10.7 mmol) in 7.5 mL of methanol and 2.5 mL of water. The mixture was then refluxed for 4 h. After cooling, the solvent was removed and the residue was diluted with saturated brine solution, extracted with EtOAc, dried (Na_2SO_4), filtered, and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 10/90% EtOAc/hexane) to yield the desired product in 66% yield (1.24 g) as orange paste. ^1H NMR (300 MHz, CDCl_3): δ 7.37 (d, $J = 8.6$ Hz, 2H), 7.33–7.25 (m, 2H), 4.28 (s, 1H), 2.64 (t, $J = 6.0$ Hz, 2H), 2.57–2.44 (m, 2H), 2.32 (t, $J = 6.9$ Hz, 2H), 2.01 (p, $J = 6.4$ Hz, 2H), 1.28 (h, $J = 7.1$ Hz, 2H), 0.71 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 196.8, 139.3, 139.1, 132.6, 129.5, 128.3, 126.7, 48.5, 37.1, 31.7, 23.0, 22.2, 11.3. IR (neat): 3351, 2956, 2927, 2873, 1662, 1608, 1488, 1191, 1091, 1016, 217, 691 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{15}\text{H}_{18}\text{ClN}\text{ONa}$ 286.0969; found 286.0981.

General Procedure F. Synthesis of Stable α -Enaminones (General Structure 27; Table 5). According to Sinha et al.²⁰ To a stirred solution of amine (1.0 equiv) in THF (1 M) was added anhydrous K_2CO_3 (2 equiv) followed by dibromopropane (10.0 equiv) at room temperature and the resultant mixture was refluxed for 16 h. The crude mixture was then filtered and concentrated in vacuo and purified by flash chromatography to yield the desired product.

2-((3-Bromopropyl)(propyl)amino)-4'-chloro-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (21a). General Procedure F was applied. α -Iminone **16b** (1.0 g, 3.8 mmol) prepared according to General Procedure E, anhydrous K_2CO_3 (1.05 g, 7.6 mmol), dibromopropane (7.6 g, 38.0 mmol) were mixed in THF (4.0 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 8/92% EtOAc/hexane) to yield the desired product in 54% yield (800 mg) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 7.33 (d, $J = 8.3$ Hz, 2H), 7.24 (d, $J = 8.3$ Hz, 2H), 3.11 (t, $J = 6.6$ Hz, 2H), 2.80 (t, $J = 6.7$ Hz, 2H), 2.61–2.73 (m, 4H), 2.51 (t, 2H), 2.04 (p, $J = 6.5$ Hz, 2H), 1.72 (p, $J = 6.7$ Hz, 2H), 1.35–1.14 (m, 2H), 0.72 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 199.3, 151.7, 142.3, 139.1, 133.5, 129.1, 128.1, 55.5, 51.3, 39.6, 32.7, 32.1, 31.8, 22.4, 21.8, 11.6. IR (neat): 2956, 2930, 2869, 1670, 1489, 1091, 1016, 823, 699 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{18}\text{H}_{23}^{81}\text{BrClN}\text{ONa}$ 408.0524; found 408.0523.

2-((3-Bromopropyl)(propyl)amino)-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (21b). General Procedure F was applied. α -Iminone **16a** (600 mg, 2.62 mmol) prepared according to General Procedure E, anhydrous K_2CO_3 (725 mg, 5.24 mmol), dibromopropane (5.3 g, 26.0 mmol) were mixed in THF (2.6 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 20/80% Ether/hexane) to yield the desired product in 81% yield (730 mg) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 7.43–7.17 (m, 5H), 3.01 (t, $J = 6.6$ Hz, 2H), 2.78 (t, $J = 6.6$ Hz, 2H), 2.69 (td, $J = 6.8, 6.1, 3.9$ Hz, 4H), 2.50 (dd, $J = 7.5, 5.9$ Hz, 2H), 2.08–1.98 (m, 2H), 1.69 (p, $J = 6.6$ Hz, 2H), 1.30–1.23 (m, 2H), 0.71 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 199.5, 153.6, 142.0, 140.8, 127.9, 127.7, 127.6, 55.7, 51.2, 39.7, 33.0, 32.2, 31.9, 22.5, 21.8, 11.6. IR (neat): 2955, 2927, 2869, 1667, 1449, 1180, 1116, 753, 697 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{18}\text{H}_{24}\text{BrN}\text{ONa}$ 372.0933; found 372.0931.

2-((3-Bromopropyl)(thiophen-2-ylmethyl)amino)-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (21c). General Procedure F was applied. The corresponding α -iminone 2-((thiophen-2-ylmethyl)-amino)-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (982 mg, 3.47 mmol), anhydrous K_2CO_3 (994 mg, 6.94 mmol), and dibromopropane (7 g, 34.7 mmol) were mixed in THF (3.5 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 1:1 DCM/hexane) to yield the desired product in 16% yield (218 mg) as pale yellow solid (mp 72–75 $^\circ\text{C}$). ^1H NMR (300 MHz, CDCl_3): δ 7.43–7.29 (m, 3H), 7.22–7.12 (m, 3H), 6.90–6.82 (m, 1H), 6.81–6.76 (m, 1H), 4.24 (s, 2H), 2.90 (t, $J = 6.9$ Hz, 2H), 2.79 (t, $J = 6.5$ Hz, 2H), 2.71 (t, $J = 6.0$ Hz, 2H), 2.59–2.51 (m, 2H), 2.06 (p, $J = 6.2$ Hz, 2H), 1.64 (p, $J = 6.8$ Hz, 2H). ^{13}C NMR (75 MHz, CDCl_3): δ 199.3, 156.0, 143.2, 141.1, 140.3, 128.1, 127.9, 127.5, 126.2, 125.0, 53.0, 50.1, 39.7, 33.2, 32.1, 31.9, 22.4. IR (neat): 2951, 2926, 2850, 1662, 1610, 1211, 755, 698 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{20}\text{H}_{22}^{81}\text{BrNOSNa}$ 428.0485; found 428.0485.

2-((3-Bromopropyl)(thiophen-2-ylmethyl)amino)-3-ethylcyclohex-2-en-1-one (25a). General Procedure F was applied. α -Iminone **14d** (705 mg, 3.0 mmol) prepared according to General Procedure E, anhydrous K_2CO_3 (830 mg, 6.0 mmol), dibromopropane (6.1 g, 30.0 mmol) were mixed in THF (3.0 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 10/90% EtOAc/hexane) to yield the desired product in 50% yield (543 mg) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 7.17 (dd, $J = 5.1, 1.3$ Hz, 1H), 6.85–6.91 (m, 1H), 6.91–6.80 (m, 1H), 4.19 (s, 2H), 3.35 (t, $J = 6.9$ Hz, 2H), 3.01 (t, $J = 7.0$ Hz, 2H),

2.51 (q, $J = 9.5$, 8.6 Hz, 2H), 2.36 (dt, $J = 8.9$, 6.4 Hz, 4H), 1.86 (dp, $J = 13.9$, 6.7 Hz, 4H), 0.97 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 198.3, 164.2, 144.4, 140.5, 126.3, 125.6, 124.6, 53.6, 51.3, 39.6, 32.4, 31.8, 29.3, 26.4, 22.3, 12.0. IR (neat): 2924, 2861, 1667, 1129, 910, 729, 702 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{16}\text{H}_{22}\text{BrNOSNa}$ 378.0498; found 378.0495.

2-((3-Bromopropyl)(propyl)amino)-3-ethylcyclohex-2-en-1-one (25b). General Procedure F was applied. α -Iminone **14a** (740 mg, 4.0 mmol) prepared according to General Procedure E, anhydrous K_2CO_3 (1.1 g, 8.0 mmol), dibromopropane (8.28 g, 40.0 mmol) were mixed in THF (4.0 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 10/90% ether/hexane) to yield the desired product in 69% yield (857 mg) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 3.39 (t, $J = 6.8$ Hz, 2H), 2.94 (t, $J = 6.9$ Hz, 2H), 2.79–2.67 (m, 2H), 2.49 (q, $J = 7.6$ Hz, 2H), 2.29–2.40 (m, 4H), 1.85 (dp, $J = 13.6$, 6.5 Hz, 4H), 1.28 (dq, $J = 15.4$, 7.7 Hz, 2H), 1.01 (t, $J = 7.6$ Hz, 3H), 0.80 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 198.4, 162.8, 141.1, 56.4, 52.3, 39.8, 32.6, 32.1, 29.2, 26.2, 22.4, 12.0, 11.8. IR (neat): 2957, 2933, 2870, 1667, 1611, 1457, 1218, 1117, 776 cm^{-1} . HRMS m/z : ($[\text{M}+\text{H}]^+$) calcd for $\text{C}_{14}\text{H}_{23}\text{BrNO}$ 302.1114; found 302.1113.

2-(Benzyl(3-bromopropyl)amino)-3-ethylcyclohex-2-en-1-one (25c). General Procedure F was applied. α -Iminone **14b** (1.2 g, 5.24 mmol) prepared according to General Procedure E, anhydrous K_2CO_3 (1.45 g, 10.48 mmol), dibromopropane (10.6 g, 52.0 mmol) were mixed in THF (5.0 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 15/85% ether/hexane) to yield enaminone in 70% yield (1.26 g) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 7.36–7.13 (m, 5H), 4.00 (s, 2H), 3.35 (t, $J = 6.9$ Hz, 2H), 3.01 (t, $J = 7.0$ Hz, 2H), 2.32–2.45 (m, 4H), 2.27 (t, $J = 6.1$ Hz, 2H), 1.92–1.77 (m, 4H), 0.85 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 198.5, 163.6, 140.5, 139.9, 129.1, 128.0, 126.8, 58.6, 51.8, 39.7, 32.5, 31.8, 29.2, 26.2, 22.3, 11.7. IR (neat): 2959, 2935, 2863, 1664, 1610, 1453, 1130, 728, 699 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{18}\text{H}_{23}\text{BrNO}$ 372.0934; found 372.0940.

2-((3-Bromopropyl)(4-methoxybenzyl)amino)-3-ethylcyclohex-2-en-1-one (25d). General Procedure F was applied. The corresponding α -iminone 3-ethyl-2-((4-methoxy-benzyl)amino)cyclohex-2-en-1-one (2.92 mg, 1.13 mmol) was prepared according to General Procedure E, using anhydrous K_2CO_3 (390 mg, 2.25 mmol), dibromopropane (2.25 g, 11.13 mmol), and THF (1.1 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 10/90% ether/hexane) to yield enaminone in 73% yield (340 mg) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 7.14 (d, $J = 8.5$ Hz, 2H), 6.79 (d, $J = 8.6$ Hz, 2H), 3.95 (s, 2H), 3.77 (s, 3H), 3.36 (t, $J = 6.9$ Hz, 2H), 3.00 (t, $J = 6.9$ Hz, 2H), 2.45–2.33 (m, 4H), 2.27 (t, $J = 6.1$ Hz, 2H), 1.90–1.81 (m, 4H), 0.88 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 198.5, 163.5, 158.5, 140.4, 132.0, 130.3, 113.4, 57.9, 55.2, 51.7, 39.8, 32.5, 31.9, 29.2, 26.2, 22.3, 11.7. IR (neat): 2935, 2835, 1663, 1610, 1510, 1245, 1172, 1034, 835, 814 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{19}\text{H}_{26}\text{BrNO}_2\text{Na}$ 402.1039; found 402.1038.

2-((3-Bromopropyl)(2-((tert-butyl)dimethylsilyloxy)ethyl)amino)-3-ethylcyclohex-2-en-1-one (25e). General Procedure F was applied. α -Iminone **14c** (1.17 g, 3.84 mmol) was prepared according to General Procedure E, using anhydrous K_2CO_3 (1.06 g, 7.7 mmol), dibromopropane (7.95 g, 38.4 mmol), and THF (4.0 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 10/90% ether/hexane) to yield enaminone in 83% yield (946 mg) as pale yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 3.52 (t, $J = 6.4$ Hz, 2H), 3.45 (t, $J = 6.7$ Hz, 2H), 2.96 (dt, $J = 19.0$, 6.6 Hz, 4H), 2.54 (q, $J = 7.7$ Hz, 2H), 2.38 (t, $J = 6.4$ Hz, 4H), 1.88 (dp, $J = 13.7$, 6.6 Hz, 4H), 1.04 (t, $J = 7.6$ Hz, 3H), 0.87 (s, 9H), 0.03 (s, 6H). ^{13}C NMR (75 MHz, CDCl_3): δ 198.1, 163.0, 141.4, 62.3, 56.8, 52.6, 39.7, 32.8, 32.1, 29.2, 26.1, 25.9, 22.4, 18.3, 12.0, –5.3. IR (neat): 2952, 2928, 2855, 1670, 1462, 1255, 1099, 939, 832, 774 cm^{-1} .

HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{19}\text{H}_{36}\text{BrNO}_2\text{SiNa}$ 442.1570; found 442.1572.

2-((3-Bromopropyl)(propyl)amino)-3-methylcyclohex-2-en-1-one (28). General Procedure F was applied. The corresponding α -iminone 3-methyl-2-(propylamino)cyclohex-2-en-1-one (330 mg, 1.98 mmol), anhydrous K_2CO_3 (545 mg, 3.96 mmol), and dibromopropane (3.87, 19.8 mmol) were mixed in THF (2.0 mL). The resultant mixture was refluxed for 16 h. After cooling, the reaction mixture was filtered and concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, 10/90% EtOAc/hexane) to yield enaminone in 79% yield (448 mg) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 3.42 (t, $J = 6.8$ Hz, 2H), 2.97 (t, $J = 6.8$ Hz, 2H), 2.76 (t, $J = 7.6$ Hz, 2H), 2.44–2.34 (m, 4H), 1.99 (s, 3H), 1.92–1.79 (m, 4H), 1.30 (h, $J = 7.8$ Hz, 2H), 0.81 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 198.1, 157.7, 141.7, 56.2, 52.0, 39.8, 32.5, 32.4, 32.2, 22.3, 22.2, 20.5, 11.8. IR (neat): 2930, 2869, 1667, 1429, 1252, 1219, 1121 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{13}\text{H}_{22}\text{BrNONa}$ 310.0777; found 310.0776.

General Procedure G. α -Enaminone (1.0 equiv) and NaI (5.0 equiv) were dissolved in acetone (0.5 M). The solution was stirred for 3 h at room temperature. The suspension was filtered and the filtrate was concentrated in vacuo. The crude mixture was purified by flash chromatography to yield the desired product.²¹

2-(benzyl(3-iodopropyl)amino)-3-ethylcyclohex-2-en-1-one (31a). General Procedure G was applied. α -Enaminone **25c** (1.05 g, 3.0 mmol) was prepared according to General Procedure F and NaI (2.25 g, 15.0 mmol) was dissolved in acetone (6.0 mL). The solution was stirred for 3 h at room temperature. The suspension was filtered and the filtrate was concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 15/85% ether/hexane) to yield iodoenaminone in 89% yield (1.06 g) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 7.31–7.13 (m, 5H), 4.00 (s, 2H), 3.12 (t, $J = 7.1$ Hz, 2H), 2.97 (t, $J = 7.0$ Hz, 2H), 2.39 (dt, $J = 16.5$, 7.3 Hz, 4H), 2.28 (t, $J = 6.1$ Hz, 2H), 1.93–1.72 (m, 4H), 0.86 (t, $J = 7.7$ Hz, 3H). ^{13}C NMR δ 198.5, 163.5, 140.5, 139.9, 129.1, 128.0, 126.8, 58.7, 53.8, 39.7, 33.3, 29.2, 26.2, 22.3, 11.7, 4.5. IR (neat): 2935, 2863, 1664, 1453, 1193, 1131, 728, 699 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{18}\text{H}_{24}\text{INONa}$ 420.0795; found 420.0794.

2-((3-Iodopropyl)(propyl)amino)-3-ethylcyclohex-2-en-1-one (31b). General Procedure G was applied. α -Enaminone **25b** (602 mg, 2.0 mmol) prepared according to General Procedure F and NaI (1.50 g, 10.0 mmol) were dissolved in acetone (4.0 mL). The solution was stirred for 3 h at room temperature. The suspension was filtered and the filtrate was concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 10/90% ether/hexane) to yield iodoenaminone in 94% yield (660 mg) as yellow liquid. ^1H NMR (300 MHz, CDCl_3): δ 3.15 (t, $J = 7.0$ Hz, 2H), 2.88 (t, $J = 6.9$ Hz, 2H), 2.73 (t, $J = 8.7$, 6.7 Hz, 2H), 2.49 (q, $J = 7.6$ Hz, 2H), 2.38–2.30 (m, 4H), 1.93–1.75 (m, 4H), 1.28 (h, $J = 7.8$ Hz, 2H), 1.01 (t, $J = 7.6$ Hz, 3H), 0.79 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 198.4, 162.8, 141.1, 56.5, 54.3, 39.8, 33.4, 29.2, 26.2, 22.5, 22.4, 12.0, 11.8, 5.0. IR (neat): 2956, 2932, 2870, 1667, 1456, 1200, 1172, 1115 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{14}\text{H}_{24}\text{INONa}$ 372.0794; found 372.0795.

2-((3-Iodopropyl)(propyl)amino)-4'-chloro-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one (31c). General Procedure G was applied. α -Enaminone **21a** (260 mg, 0.67 mmol) was prepared according to General Procedure F and NaI (500 mg, 3.35 mmol) was dissolved in acetone (1.4 mL). The solution was stirred for 3 h at room temperature. The suspension was filtered and the filtrate was concentrated in vacuo. The crude mixture was purified by flash chromatography (silica gel, 5/95% ether/hexane) to yield 2-((3-iodopropyl)(propyl)amino)-4'-chloro-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one in 93% yield (269 mg) as yellow oil. ^1H NMR (300 MHz, CDCl_3): δ 7.35 (d, $J = 8.7$ Hz, 2H), 7.29–7.22 (m, 2H), 2.90 (t, $J = 6.8$ Hz, 2H), 2.78–2.63 (m, 6H), 2.55–2.49 (m, 2H), 2.05 (p, $J = 6.3$ Hz, 2H), 1.70 (p, $J = 6.8$ Hz, 2H), 1.37–1.21 (m, 2H), 0.73 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3): δ 199.3, 151.4, 142.4, 139.1, 133.5, 129.1, 128.1, 55.5, 53.3, 39.6, 32.7, 32.6, 22.4, 21.8, 11.6, 5.2. IR (neat): 2955, 2929, 2666, 1670, 1489, 1201, 1090, 822, 731 cm^{-1} . HRMS m/z : ($[\text{M}+\text{Na}]^+$) calcd for $\text{C}_{18}\text{H}_{23}\text{ClINOINa}$ 454.0405; found 454.0407.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.7b00516.

- The spectra for new compounds (PDF)
- X-ray crystallographic data for **3d** (CIF)
- X-ray crystallographic data for **17a** (CIF)

■ AUTHOR INFORMATION

Corresponding Author

*dmitryt@ekmd.huji.ac.il

ORCID

Dmitry Tselikhovsky: 0000-0002-1581-5291

Author Contributions

[†]D.L. and G.A. contributed equally.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This project was financially supported by Yissum Research Development Company of the Hebrew University of Jerusalem.

■ REFERENCES

- (1) (a) Negri, G.; Kascheres, C.; Kascheres, A. J. *J. Heterocyclic Chem.* **2004**, *41*, 461. (b) Greenhill, J. V. *Chem. Soc. Rev.* **1977**, *6*, 277.
- (2) Rappoport, Z. *Enaminones as Synthones, in Enamines*; John Wiley & Sons: Chichester, 1994; Chapter 10, pp 523–637.
- (3) (a) Yamamoto, S.; Okamoto, K.; Murakoso, M.; Kuninobu, Y.; Takai, K. *Org. Lett.* **2012**, *14*, 3182. (b) Kascheres, C. M. *J. Braz. Chem. Soc.* **2003**, *14*, 945. (c) Gu, Z.-Y.; Zhu, T.-H.; Cao, J.-J.; Xu, X.-P.; Wang, S.-Y.; Ji, S.-J. *ACS Catal.* **2014**, *4*, 49. (d) Reddy, B. V. S.; Reddy, M. R.; Rao, Y. G.; Yadav, J. S.; Sridhar, B. *Org. Lett.* **2013**, *15*, 464. (e) Li, Y.; Xu, H.; Xing, M.; Huang, F.; Jia, J.; Gao, J. *Org. Lett.* **2015**, *17*, 3690. (f) Skötsch, C.; Breitmaier, E. *Chem. Ber.* **1978**, *111*, 2003. (g) Peng, H.; Li, J.; Wang, F.; Liu, B.; Yin, B. *J. Org. Chem.* **2016**, *81*, 4939. (h) Stanovnik, B.; Svete, J. *Chem. Rev.* **2004**, *104*, 2433.
- (4) (a) Cossy, J.; Poitevin, C.; Sallé, L.; Pardo, D. G. *Tetrahedron Lett.* **1996**, *37*, 6709. (b) Kasum, B.; Prager, R. H.; Tsopelas, C. *Aust. J. Chem.* **1990**, *43*, 355. (c) Tobias, M. A.; Strong, J. G.; Napier, R. P. *J. Org. Chem.* **1970**, *35*, 1709. (d) Rueping, M.; Parra, A. *Org. Lett.* **2010**, *12*, 5281.
- (5) (a) Parsons, A. F.; Williams, D. A. *Tetrahedron* **1998**, *54*, 13405. (b) Shi, H.; Guo, T.; Zhang-Negrerie, D.; Du, Y.; Zhao, K. *Tetrahedron* **2014**, *70*, 2753.
- (6) (a) El Bialy, S. A. *Nat. Prod. Res.* **2008**, *22*, 1176. (b) Parsons, A. F.; Williams, D. A. *Tetrahedron* **2000**, *56*, 7217. (c) Ishibashi, H.; Fuke, Y.; Yamashita, T.; Ikeda, M. *Tetrahedron: Asymmetry* **1996**, *7*, 2531. (d) Martins, F. J. C.; Viljoen, A. M.; Strydom, S. J.; Fourie, L.; Wessels, P. L. *Tetrahedron* **1988**, *44*, 591. (e) Massa, S.; Stefancich, G.; Artico, M.; Corelli, F.; Silvestri, R. *Farmaco. Ed. Sci.* **1987**, *42*, 567. (f) Arnould, J. C.; Cossy, J.; Pete, J. P. *Tetrahedron* **1981**, *37*, 1921.
- (7) Kuckländer, U.; Schneider, B. *Arch. Pharm.* **1993**, *326*, 287.
- (8) (a) Polozov, G. I.; Tishchenko, I. G. *Vesti Akad. Navuk BSSR, Ser. Khim. Navuk* **1978**, *3*, 62. (b) Shi, H.; Guo, T.; Zhang-Negrerie, D.; Du, Y.; Zhao, K. *Tetrahedron* **2014**, *70*, 2753.
- (9) (a) Curcumelli-Rodostamo, M.; MacLean, D. B. *Can. J. Chem.* **1962**, *40*, 1068. (b) Li, H.; Wang, X.; Hong, B.; Lei, X. *J. Org. Chem.* **2013**, *78*, 800. (c) Hirasawa, Y.; Tanaka, T.; Kobayashi, J. I.; Kawahara, N.; Goda, Y.; Morita, H. *Chem. Pharm. Bull.* **2008**, *56*, 1473. (d) Wang, B. H.; Lu, Z. X.; Poly, G. M. *Planta Med.* **1997**, *63*, 494. (e) Zuo, Z.; Xie, W.; Ma, D. *J. Am. Chem. Soc.* **2010**, *132*, 13226. (f) Ayer, W. A.; Iverach, G. *Can. J. Chem.* **1964**, *42*, 2514. (g) Belattar, A.; Saxton, J. E. *J. Chem. Soc., Perkin Trans. 1* **1992**, *6*, 679. (h) Li, S.; Li, Y.; Lu, C.; Zhang, J.; Zhu, J.; Wang, H.; Shen, Y. *Org. Lett.* **2015**, *17*, 3706.
- (10) (a) Brennan, J. P.; Saxton, J. E. *Tetrahedron Lett.* **1985**, *26*, 1769. (b) Belattar, A.; Saxton, J. E. *J. Chem. Soc., Perkin Trans. 1* **1992**, *1*, 679.

(c) Stork, G.; Niu, D.; Fujimoto, A.; Koft, E. R.; Balkovec, J. M.; Tata, J. R.; Dake, G. R. *J. Am. Chem. Soc.* **2001**, *123*, 3239.

(11) Trost, B. M.; Bartlett, M. J. *Org. Lett.* **2012**, *14*, 1322.

(12) All attempts to increase the conversion rate by elevating the temperature or prolonging the reaction time resulted in decomposition of starting materials.

(13) 1D NOESY and COSY NMR experiments were carried out to assign the *E*-stereoselectivity of the transformation (see spectral data).

(14) The thermodynamic experiment was conducted at a lower temperature, for longer time; NaOt-Bu rather than NaOMe was used to avoid the side product formation from a 1,2-nucleophilic addition of the methoxide to the carbonyl group of products.

(15) (a) Szostak, M.; Fazakerley, N. J.; Parmar, D.; Procter, D. J. *Chem. Rev.* **2014**, *114*, 5959. (b) St Jean, D. J.; Molander, G. A. *J. Org. Chem.* **2002**, *67*, 3861. (c) Krief, A.; Laval, A. M. *Chem. Rev.* **1999**, *99*, 745.

(16) (a) Gu, Q.; Zheng, Y. H.; Li, Y. C. *Steroids* **2006**, *71*, 96. (b) Wipf, P.; Venkatraman, S. *J. Org. Chem.* **1993**, *58*, 3455.

(17) Ikeda, M.; Uchino, T.; Matuyama, K.; Sato, A. *Heterocycles* **1988**, *27*, 2349.

(18) Benedetti, F.; Forchiassin, M.; Pispisa, G.; Nitti, P.; Pitacco, G.; Russo, C.; Valentin, E. *ChemInform* **1990**, *21*, 43.

(19) Cossy, J.; Pete, J. P. *Tetrahedron Lett.* **1980**, *21*, 2947.

(20) Majumdar, K. C.; Nath, S.; Chattopadhyay, B.; Sinha, B. *Synthesis* **2010**, *2010*, 3918.

(21) Finkelstein, H. *Ber. Dtsch. Chem. Ges.* **1910**, *43*, 1528.